Supplementary Figure S7 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer | Synapse
June 3, 2024Open Access
Supplementary Figure S7 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S7. Distribution of 225Ac-pelgi and 225Ac-DOTA-pelgi in the MDA-PCa-2b prostate cancer CDX model.